Video: A decade of open access

What has made Nature Communications successful over the past ten years, and what to do the editors have in store for the next decade? 
Video: A decade of open access
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Nature Communications launched in 2010 as the first online-only, hybrid journal from Nature Research. Join our anniversary celebration with a video from past and present Chief Editors.

Featuring:

  • Elisa De Ranieri | Editor in Chief, Nature Communications
  • Magdalena Skipper | Editor in Chief, Nature (Former Editor in Chief, Nature Communications)
  • Enda Bergin | Chief Physical Sciences Editor, Nature Communications
  • David Gevaux | Editorial Director, Nature Research & BMC Physical Sciences Community Journals (Former Chief Physical Sciences Editor, Nature Communications)
  • Nathalie Le Bot | Chief Life Sciences Editor, Nature Communications
  • Niki Scaplehorn | Editorial Director, Nature Life Science Journals (Former Chief Life Sciences Editor, Nature Communications)

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Biotechnology
Life Sciences > Biological Sciences > Biotechnology

Related Collections

With Collections, you can get published faster and increase your visibility.

Women's Health

A selection of recent articles that highlight issues relevant to the treatment of neurological and psychiatric disorders in women.

Publishing Model: Hybrid

Deadline: Ongoing

Tumor Microenvironment Crosstalk and Therapeutic Implications

With this cross-journal Collection, the editors at Nature Immunology, Nature Communications, Communications Medicine and Scientific Reports invite manuscripts that highlight cutting-edge research on TME crosstalk and its therapeutic implications. Topics of interest include immune modulation and checkpoint pathways, cancer-associated fibroblasts and stromal remodeling, angiogenesis and vascular normalization, metabolic reprogramming within the TME, and the role of microbiota in tumor-immune dynamics. We also welcome studies on novel therapeutic approaches that exploit TME vulnerabilities to advance cancer treatment.

Publishing Model: Hybrid

Deadline: Nov 02, 2026